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Type-2 diabetes prevalence is continuing to rise worldwide due to physical inactivity
and obesity epidemic. Diabetes and fluctuations of blood sugar are related to multiple
micro- and macrovascular complications, that are attributed to oxidative stress,
endoplasmic reticulum (ER) activation and inflammatory processes, which lead to
endothelial dysfunction characterized, among other features, by reduced availability
of nitric oxide (NO) and aberrant angiogenic capacity. Several enzymatic anti-oxidant
and anti-inflammatory agents have been found to play protective roles against oxidative
stress and its downstream signaling pathways. Of particular interest, heme oxygenase
(HO) isoforms, specifically HO-1, have attracted much attention as major cytoprotective
players in conditions associated with inflammation and oxidative stress. HO operates as
a key rate-limiting enzyme in the process of degradation of the iron-containing molecule,
heme, yielding the following byproducts: carbon monoxide (CO), iron, and biliverdin.
Because HO-1 induction was linked to pro-oxidant states, it has been regarded
as a marker of oxidative stress; however, accumulating evidence has established
multiple cytoprotective roles of the enzyme in metabolic and cardiovascular disorders.
The cytoprotective effects of HO-1 depend on several cellular mechanisms including
the generation of bilirubin, an anti-oxidant molecule, from the degradation of heme;
the induction of ferritin, a strong chelator of free iron; and the release of CO, that
displays multiple anti-inflammatory and anti-apoptotic actions. The current review article
describes the major molecular mechanisms contributing to endothelial dysfunction
and altered angiogenesis in diabetes with a special focus on the interplay between
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oxidative stress and ER stress response. The review summarizes the key cytoprotective
roles of HO-1 against hyperglycemia-induced endothelial dysfunction and aberrant
angiogenesis and discusses the major underlying cellular mechanisms associated with
its protective effects.
Keywords: heme oxygenase-1 (Ho-1), endothelial dysfunction, angiogenesis, oxidative stress, ER stress,
diabetes, hyperglycemia
INTRODUCTION
Endothelial dysfunction is considered as the structural alteration
and functional impairment of vascular endothelial layer,
characterized by a reduction in NO bioavailability and aberrant
angiogenesis (Lerman and Burnett, 1992; Creager et al., 2003;
Jamwal and Sharma, 2018). Endothelial dysfunction is a key
player in the pathological onset of various cardiovascular
complications associated with diabetes, whether affecting
microvasculature including retinopathy, nephropathy, and
neuropathy or macrovasculature such as ischemic heart
disease and ischemic stroke (Ebrahimian et al., 2006). There
is much scientific evidence showing that hyperglycemia, a
characteristic manifestation of diabetes, is implicated in the
development of endothelial dysfunction. Other molecular
mechanisms involved in vascular endothelial perturbations
that ensue in such a metabolic disorder include disruption
of a large array of metabolic pathways within the endothelial
cell leading to endoplasmic reticulum (ER) stress, oxidative
stress, inflammation and apoptosis (Cimellaro et al., 2016;
Incalza et al., 2018).
Heme oxygenase (HO) is a cytoprotective enzyme, which
contributes to maintaining a healthy vascular endothelium.
HO operates as a key rate-limiting enzyme in the process of
degradation of the iron-containing molecule, heme, yielding
the following byproducts: carbon monoxide (CO), iron, and
biliverdin (Kikuchi et al., 2005; Ryter et al., 2006; Rochette
et al., 2018). There are two main HO isoforms known (HO-
1, HO-2), in addition to a putative third one (HO-3) (Nitti
et al., 2017). Among the three isoforms, the role of HO-1 as a
major protective enzyme is best documented. Its anti-oxidant,
anti-apoptotic (Wang et al., 2010; Mishra and Ndisang, 2014;
Tiwari and Ndisang, 2014), and anti-inflammatory (Hayashi
et al., 1999; Lee and Chau, 2002; Morse et al., 2003; Ndisang and
Jadhav, 2009) effects have attracted much interest in literature.
The cytoprotective effects of HO-1 depend on multiple cellular
processes including the generation of bilirubin, an anti-oxidant
molecule, from the degradation of heme; the induction of ferritin,
a strong chelator of free molecular iron; and the liberation of
CO, responsible for HO-1 major anti-inflammatory and anti-
apoptotic effects (Durante, 2003; Tiwari and Ndisang, 2014).
However, the anti-inflammatory and anti-apoptotic effects of
CO are only observed if CO is generated in low levels. Large
amounts of CO can have lethal consequences because of the
strong affinity of CO binding to the heme in hemoglobin and
mitochondrial proteins. CO is a stable non-radical small gas
molecule that is weakly soluble in water. It belongs to the
family of gasotransmitters which emerged as important signaling
molecules. CO signals inside the cell in several manners. For
instance, CO stimulates guanylyl cyclase to form cGMP and
regulates the action of some transcription factors (Mustafa et al.,
2009; Garcia-Mata and Lamattina, 2013).
HO-1 is induced by a variety of pro-oxidant agents and
stimuli, such as ultraviolet rays, heavy metals, inflammatory
cytokines and iron-containing molecule, heme (Li et al.,
2011). HO-1 is now recognized for playing anti-oxidative
and cytoprotective roles both in vitro and in vivo. For
example, mice deficient for HO-1 were found to spontaneously
develop iron depots in kidneys and livers, tissue damage,
chronic inflammation and oxidative structure modification of
macromolecules (e.g., proteins, DNA) (Poss and Tonegawa,
1997a,b). Similar to animal models, the first reported human
case of HO-1 deficiency involved significant iron tissue depots,
growth deficiency, anemia and high susceptibility to reactive
oxygen species (ROS)-mediated damage (Yachie et al., 1999).
At the molecular level, it is believed that HO-1 protects
vessel wall from pathological remodeling and endothelial cell
dysfunction (Duckers et al., 2001; Durante, 2003; Awede
et al., 2010; Hyvelin et al., 2010). Several methodologies were
employed to induce HO-1 in the vessels with the use of
pharmacological inducers being one of the most promising
approaches (Awede et al., 2010; Hyvelin et al., 2010). Heme
itself and its man-made analogs are strong pharmacological
inducers of HO-1 and were found to protect against the
development of cardiovascular diseases in several studies both
in vitro and in vivo (Awede et al., 2010; Hyvelin et al.,
2010; Li et al., 2011). A study conducted by Yang et al.
(2015) where the serum of rats exposed to cigarette smoke
was used to induce oxidative stress in human umbilical vein
endothelial cells (HUVECs), has shown a significant decrease
in endogenous production of ROS following the induction of
HO-1 by hemin (Yang et al., 2015). Maamoun et al. (2017)
found that the pharmacological induction of HO-1 using Cobalt-
protoporphyrin (CoPP) reduced ROS production in HUVECs
exposed to intermittent high glucose.
With regards to the anti-inflammatory effects of HO-
1, Chang et al. (2014) have shown that the treatment of
HUVECs with iodine contrast medium caused anti-proliferative
and inflammatory reactions, and enhanced the expression
of intercellular adhesion molecule (ICAM)-1 and adhesion
molecules receptors while cells co-incubated with the HO-1
inducer were completely protected (Chang et al., 2014). The
cytoprotective role of HO-1 has also been illustrated in cancer
cells, where one study has demonstrated that the upregulation
of HO-1 in renal cancer cells promoted their survival capacity
via the induction of the expression of pro-survival molecule
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Bcl-xL and decreased expression of Beclin-1 and LC3B-II, that
are involved in the process of autophagy, an effect that has
been reversed by HO-1 knockdown (Banerjee et al., 2012).
Furthermore, in vascular cells, it has been found that HO-1
induction protected HUVECs from high glucose mediated cell
death through the reduction of caspases 3 and 7 activation
(Maamoun et al., 2017).
In the current article, we have reviewed the major
mechanisms contributing to endothelial dysfunction, the
key initial step in the onset of atherosclerotic process, in the
context of diabetes and hyperglycemia. Furthermore, we have
reviewed the cytoprotective roles of HO-1 against diabetes- and
hyperglycemia-induced endothelial dysfunction and aberrant
angiogenesis and discussed the major underlying molecular
mechanisms associated with these protective effects with special
emphasis on signaling pathways related to oxidative stress and
ER stress response.
ENDOTHELIAL DYSFUNCTION AND
HYPERGLYCEMIA: KEY MOLECULAR
DISTURBANCES
The endothelium is a single cell layer that forms the interface
between blood stream and adjacent tissues. Over the recent
decades the complexity of this selectively permeable barrier and
its important contribution to controlling vascular homeostasis
have been established (Michiels, 2003; Khazaei et al., 2008;
Jamwal and Sharma, 2018). The endothelium allows the selective
passage of certain substances such as nutrients through the vessel
wall to the adjacent tissues. The endothelium is recognized as
an endocrine organ that is able to produce and secrete many
hormones and mediators which are crucial for the optimal
functioning of the vasculature such as factors regulating vascular
tone, coagulation, immune response and growth of adjacent
vascular cells (Khazaei et al., 2008; Jamwal and Sharma, 2018).
In normal physiological conditions, vascular endothelial cells
are exposed to plasma blood sugar levels between 3.8 and
6.1 mmol/L. Exposure of endothelial cells to glucose levels of
11.1 mmol/L and above is regarded as a diabetic condition
[the national institute for health and care excellence (NICE)
guidelines, 2015]. However, unlike in vivo conditions, in cell
culture, the definition of high glucose varies considerably
according to the cell model used, depending on glucose levels
in culture medium where the cells are being selected and
harbored. Two examples that demonstrate such variability are
the endothelial cell line EA.hy926 and HUVECs, where the
former is propagated in culture medium containing 25 mM
glucose, whereas the latter is routinely grown in a culture medium
containing 5.5 mM of glucose (Maamoun et al., 2017). As a result,
25 mM glucose would be considered to be a high concentration
of glucose for HUVECs, but is a standard level in EA.hy626
endothelial cell culture medium. Alterations occur in both the
micro- and macrovasculature in response to hyperglycemia. An
abnormally high glucose concentration can disrupt the balance
within the endothelial cell and a state of ‘endothelial cell
dysfunction’ results. Endothelial cell dysfunction is defined by
the presence of one or more of the following characteristics: (I)
low bioavailability of NO, (II) impaired endothelium-dependent
relaxation, (III) weak fibrinolytic capability, (IV) excess of
production of growth factors, adhesion molecules and pro-
inflammatory molecules (e.g., cytokines), oxidative stress, and
aberrant angiogenesis (Cade, 2008).
Hyperglycemia-Mediated Oxidative
Stress and Endothelial Injury
Macrovascular and microvascular complications have been
shown to be mainly or partly dependent on hyperglycemia
(Zoungas et al., 2012). Hyperglycemia can induce vascular
endothelial damage through different pathways: (I) enhanced
polyol activity, causing sorbitol and fructose accumulation;
(II) enhanced production of advanced glycation end products
(AGEs); (III) activation of mitogenic protein kinase C (PKC);
(IV) heightened hexosamine flux pathway and (V) a decrease
of body anti-oxidant defenses (Brownlee, 2001; Kornfeld et al.,
2015). There is considerable evidence that these biochemical
pathways can be induced by excessive generation of ROS,
leading to increased oxidative stress in a positive feedback loop
(Son, 2012). Oxidative stress occurs when the concentrations
of ROS exceed those of anti-oxidant neutralizing species, such
as glutathione (GSH) and HO. ROS are a heterogeneous
population of molecules including free radicals, such as
hydroxyl radical (OH−), superoxide anion (O2−), peroxyl
(RO2), and hydroperoxyl (HRO2−), and non-charged species,
such as hydrogen peroxide (H2O2) and hydrochloric acid
(HCl) (Pieper et al., 1997). Under intracellular hyperglycemic
conditions, excessive production of ROS develops through
several mechanisms, the most important of which is excessive
activation of mitochondrial electron transport chain. Other
sources of ROS include glucose-induced activation of NADPH
oxidase (NOX) and xanthine oxidase (Nishikawa et al., 2000).
This excessive ROS production inflicts DNA damage resulting
in poly ADP ribose polymerase (PARP)-1 activation, which in
turn inhibits the glycolytic enzyme glyceraldehyde-3-phosphate
dehydrogenase (G3PDH) resulting in the pile-up of upstream
glycolytic metabolites, with the resulting influx into polyol
pathway, hexosamine pathway, diacylglycerol (DAG) and PKC
pathway, as well as generation of AGEs (Du et al., 2003)
(Figure 1).
Glucose, through the polyol pathway, is converted into
polyalcohol sorbitol by aldose reductase utilizing NADPH as a
cofactor, which in turn reduces intracellular concentrations of
NADPH resulting in the inhibition of glutathione/peroxidase
anti-oxidant system, which is dependent on NADPH as a
cofactor, and consequently induces overproduction of H2O2
and ROS in general. Moreover, ROS accumulation inhibits
glucose-6-phosphate dehydrogenase (G6PDH), which is the
rate limiting enzyme for pentose shunt pathway that is
fundamental to the maintenance of reducing equivalents for the
glutathione/peroxidase system anti-oxidant system, amplifying
the oxidative stress (Figure 2). Furthermore, sorbitol is oxidized
to fructose by sorbitol dehydrogenase using NAD as a co-
factor, increasing the intracellular ratio of NADH/NAD+,
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FIGURE 1 | Intracellular hyperglycemia results in increased production of mitochondrial ROS. ROS cause DNA damage releasing PARP-1 which inhibits G3PDH. This
results in the accumulation of upstream glycolytic intermediates. Other pathways are activated as a result of the accumulation of glycolytic intermediates upstream of
G3P which have detrimental effects on the cell; these pathways are; (1) Polyol pathway which depletes the cell of its antioxidant GSH system due to scavenging of
NADPH, thereby augmenting ROS production, (2) Methylglyoxal which is a precursor to AGEs/RAGEs which activate pro-inflammatory and pro-oxidant molecules,
(3) DAG/PKC which impairs insulin signaling and eNOS activity, activates pro-inflammatory and pro-oxidant molecules, (4) Hexosamine pathway with the resultant
activation of pro-inflammatory molecules, inhibition of eNOS at the Akt activation site and activation of TGF-β with increase in ROS. All these pathways increase ROS
in a positive feedback loop. AGEs, advanced glycation end products; DAG, diacylglycerol; eNOS, endothelial NO synthase; G3PDH, Glyceraldehyde 3-phosphate
dehydrogenase; GSH, Glutathione; ICAM-1, intracellular adhesion molecule-I; IL-6, interleukin 6; NAD, nicotinamide adenine dinucleotide; NADP, NAD phosphate;
NF-κB, nuclear factor kappa B; NO, nitric oxide; PARP-1, poly ADP ribose polymerase 1; PKC, protein kinase C; RAGE, AGEs receptor; ROS, reactive oxygen
species; TGF-β, transforming growth factor β; TNF-α, tumor necrosis factor α; VCAM-1, vascular cell adhesion molecule 1. The symbol means inhibition.
exacerbating the inhibition of G3PDH which is dependent
on NAD as a cofactor; thus amplifying the accumulation of
glyceraldehyde-3-phosphate (G3P) with the consequent flux into
triose phosphate pathway via triose phosphate isomerase (TPI)
yielding dihydroxyacetone phosphate (DHAP). Higher levels of
triose phosphate promote the formation methylglyoxal and DAG.
Methylglyoxal is a precursor of AGEs, which are formed by
binding of methylglyoxal to the free amino groups of intracellular
and extracellular proteins (Allaman et al., 2015; Maessen et al.,
2015) (Figure 3).
DAG activates certain PKC isoforms by binding to their
membrane-bound receptors. Consequently, active PKC isoforms
may contribute to hyperglycemia-induced vascular endothelial
damage by inhibiting insulin-stimulated endothelial NO synthase
(eNOS) expression and NO production in endothelial cells,
increasing thus the activity of nuclear factor kappa B (NF-κB)
and the pro-oxidant enzyme NOX (Giri et al., 2018). Under
hyperglycemic conditions, PKC-α and PKC-γ, were reported
to be able to enhance NOX activity (Venugopal et al., 2002;
Dasu et al., 2008). PKC-β, a molecular mediator of hypertrophic
responses, was also found to be selectively over-activated in
vascular and cardiac cells of animal models of diabetes. Liu et al.
(2012) observed that the selective inhibition of PKC-β, improved
left ventricular function and structure in a diabetes animal model
of streptozotocin-injected rats. More recently, it was reported
that the activation of PKC-α in the intestine of streptozotocin-
induced diabetic mice contributed to the enhanced uptake
of iron leading to iron loading that contributes to diabetic
complications (Zhao et al., 2018). Furthermore, the inhibition
of PKC-ζ was shown recently to improve insulin sensitivity and
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FIGURE 2 | Pentose phosphate pathway (PPP) is inhibited by hyperglycemia and ROS. Hyperglycemia-induced ROS cause the inhibition of G6PDH which is the
rate limiting enzyme for this pathway. This results in reduced NADPH production, a cofactor fundamental in the GSH/peroxidase antioxidant system, with the
consequent buildup of more ROS causing a vicious circle of oxidative stress induction. G6PDH, glucose-6-phosphate dehydrogenase; GSH, glutathione; NADPH,
reduced NAD phosphate. The symbol means inhibition.
FIGURE 3 | Polyol and triose phosphate pathways activation caused by hyperglycemia-induced ROS. Hyperglycemia results in an excess of ROS production which
inhibits G3PDH with the consequent accumulation of glycolytic intermediates upstream to G3P leading to increase flux into other pathways, namely polyol and triose
phosphate. In polyol pathway, NAD reducing equivalent is consumed by sorbitol dehydrogenase reaction leading to reductions in NAD levels inside the cell which
further confounds the inhibition of G3PDH. DHAP, dihydroxyacetone phosphate; G3PDH, glyceraldehyde 3-phosphate dehydrogenase; NAD, nicotinamide adenine
dinucleotide; TPI, triose phosphate isomerase. The symbo means inhibition.
uptake of glucose in rat adipocytes rendered insulin-resistant by
incubating them in high glucose and high insulin concentrations
(Lu et al., 2018).
Hyperglycemia-induced ROS overproduction is also caused by
the interaction of AGEs with their receptors (RAGEs) (Rochette
et al., 2014). This interaction generates intracellular ROS and
activates NF-κB, which modulates the expression of a many
genes associated with inflammation and vascular remodeling,
including interleukin (IL)-6, tumor necrosis factor (TNF)-
α, ICAM-1, vascular cell adhesion molecule (VCAM)-1 and
monocyte chemotactic protein-1 (MCP-1) (Bierhaus et al., 2001;
Younce et al., 2010). Furthermore, AGEs which are present in the
extracellular matrix can decrease the availability of NO, reducing
thereby endothelium-dependent vasodilation (Xu B. et al., 2005).
Finally, the activation of the hexosamine pathway contributes
to the vascular damage induced by hyperglycemia owing to its
capacity to disturb multiple cellular processes, including signal
transduction, gene transcription, cell survival, and proteasome-
mediated degradation (Love and Hanover, 2005). The activation
of the hexosamine pathway can inhibit eNOS activity by
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impairing insulin receptor activation and signal transduction and
increasing ROS production (Rajapakse et al., 2009a,b).
ER Stress and Endothelial Dysfunction in
Diabetes
In addition to hyperglycemia-induced oxidative stress, ER
stress was also linked to various features of endothelial
dysfunction in diabetics with decreased NO bioavailability and
aberrant angiogenesis being two prominent features (Sheikh-
Ali et al., 2010). Aberrant angiogenesis may be either an
excessive angiogenic response (e.g., retinopathy, nephropathy)
or a deficiency in angiogenesis (e.g., disturbed wound healing,
reduced sprouting of collateral vessels, neuropathy, ischemia and
peripheral vascular disease) (Kota et al., 2012). Under normal
physiological conditions, the ER plays a central role in protein
synthesis and co-translational protein modification through the
folding of newly synthesized proteins by native disulfide bond
formation to attain the final stable conformational state prior
to being directed to their final destination whether it is to be
secretory or membrane bound proteins. The homeostasis of ER is
put at stress when the influx of the newly synthesized misfolded
or unfolded polypeptide chains exceeds the repair and refolding
capacity of the ER; this condition is commonly referred to as ER
stress response (Walter and Ron, 2011).
Endoplasmic reticulum stress response develops both in
type-1 or type-2 diabetes mellitus due to the presence of
hyperglycemia that increases the demand for the synthesis of
enzymatic machinery necessary to carry out complete glucose
oxidation through glycolysis, tricarboxylic acid cycle (TCA) and
oxidative phosphorylation by mitochondrial electron transport
chain (Flamment et al., 2012; Hu et al., 2017). This increase in
protein load on the ER increases the chances of accumulation
of unfolded or poorly folded proteins inside the ER by the
formation of incorrect or non-native disulfide bonds due to
mispairing of cysteine residues in the protein being synthesized
(Lisa et al., 2012). When this occurs, the cell triggers the unfolded
protein response (UPR), which aims to resolve the problem
by three different mechanisms working synergistically together:
(I) Enhancement of gene expression of molecular chaperones
to support and improve the correct folding of proteins; (II)
Activation of ER-associated degradation machinery (ERAD) to
get rid of aberrant proteins; and (III) Attenuation of translation
rate to slow down the entry of new proteins to the ER
lumen (Flamment et al., 2012). The molecular system involved
in such response includes three membrane-bound proteins
that orchestrate the whole process, namely inositol requiring
enzyme (IRE)-1α, protein kinase RNA-like ER kinase (PERK)
and activating transcription factor (ATF)-6, which under basal
conditions are kept in an inactive state by binding to 78 kDa
glucose-regulated protein (GRP)-78 or binding immunoglobulin
protein (BiP); however, when there is an increase of misfolded
proteins, GRP78/BiP preferentially binds to them hence relieving
those ER effectors from their inhibition state. The dissociation of
GRP78 from the three effectors is followed by the dimerization
and hence activation of both IRE-1α and PERK, and the transfer
of ATF-6 to the Golgi body for proteolytic processing activation
before the final active ATF-6 translocates to the nucleus and
stimulates the transcription of target genes. The UPR is a
physiological pro-survival process which attempts to restore
normal homeostatic state of the ER within the cell; however,
if the stress condition remains unresolved, these three effectors
involved in the UPR can also activate multiple inflammatory
responses and eventually may lead to cell death through the
activation of several pro-apoptotic sub-pathways (Gardner and
Walter, 2011; Walter and Ron, 2011; Hassler et al., 2012; Gardner
et al., 2013) (Figure 4).
Previous studies have demonstrated the role of ER stress
response in endothelial cell inflammation and cell death in
vascular diseases associated with diabetes. Work by Chen et al.
(2012) demonstrated that the ATF-4-mediated activation of
signal transducer and activator of transcription 3 (STAT3) is
responsible for inflammation, vascular endothelial damage and
loss of angiogenic capacity in streptozotocin-induced wild-type
mouse model of type-1 diabetes, while ATF-4 knockout mice
were protected. Other in vitro studies have also shown that
the blockade of STAT3 reduced high glucose-mediated ER
stress response activation, suggesting a crosstalk between ER
stress and inflammatory signaling pathways. Moreover, another
study of diabetic cardiovascular complications in streptozotocin-
induced mouse model of diabetes found that the activation of
the epidermal growth factor receptor (EGFR) tyrosine kinase
signaling pathway participated in the induction of ER stress
response and microvascular dysfunction in these mice. Enhanced
EGFR phosphorylation was associated with the activation
of the PERK/eukaryotic initiation factor (eIF)-2α/ATF-4 axis.
The pharmacologic blockade of the kinase activity of EGFR
ameliorated endothelium-dependent relaxation and increased
NO production (Galan et al., 2012). Previously, Agouni et al.
(2011) investigated in a mouse model of diet-induced obesity the
impact of whole-body alleviation of ER stress response through
the specific liver-deletion of protein tyrosine phosphatase (PTP)-
1B, a protein located on the luminal surface of the ER that was
shown to be implicated in the activation of ER stress (Owen
et al., 2013), on endothelial cell function. Authors reported that
the alleviation of ER stress response improved endothelium-
dependent vasodilation in mouse aortas and improved vascular
NO bioavailability (Agouni et al., 2014).
The role of ER stress in ischemia-induced neovascularization
was demonstrated in type-2 diabetes genetic mouse model
(db/db). The chemical chaperones, tauroursodeoxycholic acid
(TUDCA) and 4-phenylbutyric acid (4-PBA), known to alleviate
ER stress, improved hind-limb ischemia after femoral artery
ligation. These small molecules reduced the expression of ATF-
4 and C/EBP homologous protein (CHOP), enhanced blood flow
recovery following ligation, and increased the expression of pro-
angiogenic factors (Amin et al., 2012). There is also growing
evidence that ER stress response might play an important role
in promoting angiogenesis, and therefore may act as a novel
mediator of the angiogenic process. This evidence implicates
these pathways in the upregulation of angiogenic factors such
as vascular endothelial growth factor (VEGF)-A, fibroblast
growth factor (FGF), IL-8, and endothelin (ET)-1 (Paridaens
et al., 2014). Notably, it was shown that ER stress-mediated
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FIGURE 4 | UPR response activation. ER membrane-bound proteins, PERK, ATF-6 and IRE-1α, are activated when unfolded proteins accumulate within the ER
lumen and GRP78/BiP dissociates from them. Downstream effects of PERK involve the phosphorylation of eIF-2α resulting in the attenuation of protein translation
with the preferential increase in ATF-4 expression. ATF-6 (p90) translocates to the Golgi body where it undergoes proteolytic cleavage. Active cleaved ATF-6 (p50)
translocates then to the nucleus and stimulates the expression of molecular chaperones to aid in the folding process. Finally, active IRE-1α through its
endoribonuclease activity undergoes intron splicing of XBP-1 mRNA to synthesize the active spliced XBP-1s which binds to the promoter regions of several genes
involved in the synthesis of chemical chaperones and ERAD proteins to restore normal protein homeostasis as part of the UPR rescue response. ATF-6, activating
transcription factor 6; BiP, binding immunoglobulin protein; eIF-2α, Eukaryotic translation initiation factor 2α; ERAD, endoplasmic-reticulum-associated protein
degradation; GRP78, 78-kDa glucose regulated protein; IRE-1α, inositol-requiring enzyme 1α; PERK, PKR-like ER kinase; XBP-1, X-box binding protein 1.
overexpression of VEGF-A was dependent on the IRE-1α/X-box
binding protein (XBP)-1, PERK/ATF-4, as well as ATF-6 arms
of ER stress response. The upregulation of VEGF-A expression
by UPR effectors was also reported in diabetic nephropathies
and retinopathies, indicating the involvement of UPR and ER
stress responses in the enhancement of angiogenesis beyond
the physiological conditions (Ghosh et al., 2010). However,
Maamoun et al. (2017) have reported more recently that the
chemical chaperone, 4-PBA prevented intermittent high glucose-
induced impaired angiogenic capacity in HUVECs characterized
by a weaker ability to form tube-like structures on a matrigel
matrix and a reduced the expression of VEGF-A. Nonetheless,
the exact molecular mechanisms involved in the switch between
pro- and anti-angiogenic stimulation by ER stress response are
not fully understood.
Endoplasmic reticulum stress also plays a key role in the onset
of atherosclerosis in diabetes, a major consequence of endothelial
dysfunction. Several independent risk factors for cardiovascular
diseases, including hyperglycemia (Werstuck et al., 2006), hyper-
homocysteinemia (Werstuck et al., 2001), obesity (Ozcan et al.,
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2004; Agouni et al., 2011), and dyslipidemia have been associated
with ER stress, indicating that it may be a converging molecular
link for atherogenesis (Cunha et al., 2008). The activation of
UPR response has been observed at all stages of atherogenesis
(Zhou et al., 2005). ER stress inducers can promote lipid tissue
accumulation by activating the sterol regulatory element binding
proteins (SREBP), which control the transcriptional regulation
of lipid synthesis and transport in endothelial cells (Colgan
et al., 2007). ER stress inducers also activate NF-κB, which
promotes the expression of pro-inflammatory and pro-coagulant
genes contributing thus to atherogenesis (Jiang et al., 2003).
Moreover, ER stress effector IRE-1α causes the activation of
c-Jun N-terminal kinases (JNK) which impairs insulin signaling
reducing thus insulin-stimulated eNOS activity with subsequent
reduction of NO production (Andreozzi et al., 2007). ER stress
has also been shown in vivo and in vitro to activate pro-apoptotic
caspases and cell death of human endothelial cells (Xu C. et al.,
2005; Maamoun et al., 2017).
There is also evidence suggesting a crosstalk between ER
stress and oxidative stress. Maintaining ER balance is intimately
associated with oxidative state of the cell. In contrast to
cytosol, the ER lumen is an oxidizing environment characterized
by an elevated ratio of oxidized to reduced glutathione
(GSSG/GSH) which encourages the proper native disulfide
bond formation (van der Vlies et al., 2003). During disulfide
bond-dependent protein folding, proteins are oxidized to form
disulfide bonds by protein disulfide isomerase which allows
proper polypeptide rearrangement to reach their final native
conformational state. Any mispairing of cysteine residues would
result in the formation of non-native disulfide bonds that prevent
proteins from achieving their native optimal conformation,
a condition that results when there is an abnormally high
request for protein synthesis as in the case of hyperglycemia.
In addition, hyperglycemia-induced AGEs accumulation as well
as hexosamine and polyol pathways activation can impair the
correct protein folding, leading to the activation of UPR and ER
stress responses (Chakravarthi and Bulleid, 2004).
In normal conditions, during protein folding, electrons are
transferred from targeted cysteine residues in the polypeptide
chain being synthesized forming native disulfide bonds to bring
the protein structure to its final conformational state. This
reaction is catalyzed by two crucial enzymes, namely protein
disulfide isomerase (PDI) and ER oxidoreductase (ERO)-1α,
which aid in this electron transfer from the target cysteine
residues to molecular oxygen, generating H2O2; however, in the
presence of a high protein folding load, as in hyperglycemia,
there is an increase in non-native disulfide bond formation,
which results in GSH consumption as a protective mechanism.
This results in GSH depletion contributing thus to excessive
ROS generation and consequent development of oxidative stress
(van der Vlies et al., 2003) (Figure 5). Moreover, hyperglycemia-
induced oxidative stress is suggested to contribute to the
inactivation of disulfide isomerases resulting in the buildup of
unfolded proteins in addition to the misfolded ones (Tu and
Weissman, 2004). Since protein folding is a highly energy-
dependent process, protein misfolding-induced ATP depletion
leads to more glucose consumption to promote mitochondrial
oxidative phosphorylation to increase ATP synthesis and
consequently increasing ROS production to pathological levels.
As a result of unfolded/misfolded protein accumulation, Ca2+
leak ensues from the ER lumen into the cytosol and increased
intracellular Ca2+ levels further stimulate mitochondrial ROS
FIGURE 5 | Schematic representation showing ER protein folding as a source of ROS. During ER stress response, there is accumulation of misfolded proteins within
the ER where non-native disulfide bonds form resulting in the depletion of glutathione (GSH) that is trying to correct the aberrant bonds. IRE-1α, inositol-requiring
enzyme 1 α; PDI, protein disulfide isomerase.
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FIGURE 6 | Hyperglycemia-induced ROS generation and activation of ER stress response. Hyperglycemia-generated ROS can promote the accumulation of
unfolded proteins within the ER contributing to ER stress response through different mechanisms. ER dysfunction causes GSH depletion, Ca2+ leak from the ER
lumen into the cytosol and into the mitochondria, and ATP depletion that can impair its structural and functional integrity and stimulate mitochondrial ROS
production. ROS, in turn, can alter protein folding, thereby inducing unfolded protein accumulation within the ER lumen. ATF-6, activating transcription factor 6; BiP,
binding immunoglobulin protein; CHOP, C/EBP homologous protein; ERAD, endoplasmic-reticulum-associated protein degradation; GSH, Glutathione; GSSG,
oxidized Glutathione; IRE-1α, inositol-requiring enzyme 1α; JNK, c-Jun N-terminal kinases; NF-κB, nuclear factor kappa B; PERK, PKR-like ER kinase; ROS, reactive
oxygen species.
production. In fact, Ca2+ increases the permeability of inner
mitochondrial membrane and blocks the electron transport chain
at the level of complex III, thereby causing electron leak to
molecular O2, thus exacerbating the ongoing ROS production
(Gorlach et al., 2006) (Figure 6). Taken together, there is
substantial evidence that both ER stress and oxidative stress are
concomitantly induced in hyperglycemic conditions and they
play an important role in the perturbations that ensue in the
vascular endothelium leading to the development of endothelial
dysfunction in diabetes.
Mitochondrial Dysfunction and
Endothelial Dysfunction in Diabetes
Much evidence suggests that mitochondrial dysfunction is a
major source for hyperglycemia-mediated generation of ROS
through the electron transport chain, which contributes to
oxidative damage pathways as discussed above, namely the
polyol, triose phosphate, hexosamine, and AGEs pathways
(Nishikawa et al., 2000). Normally, NADH and FADH2 released
from the TCA cycle translocate from the mitochondrial matrix
to the inner mitochondrial membrane, where they will donate
free electrons to the series of mitochondrial membrane-bound
complexes. Free electrons are transferred through mitochondrial
complexes I, II, III and cytochrome c (IV), until they are
finally transferred to molecular oxygen to form water. The
electron transfer across these complexes generates a gradient of
protons in the mitochondrial intermembrane space, generating
thus a proton potential gradient across the inner mitochondrial
membrane, which activates ATP synthesis. When electrons
are moving from complex III to complex IV, ROS radicals
are generated in small amounts during normal oxidative
phosphorylation process; these ROS radicals are then captured
by enzymatic anti-oxidants such as glutathione (GSH) and
superoxide dismutase (SOD) isoforms. Under hyperglycemic
conditions, higher levels of glucose-derived pyruvate and acetyl-
CoA enter the TCA cycle increasing thus the generation of
NADH and FADH2 that, in turn, transfer free electrons into
the electron transport chain and consequently massively increase
proton gradient through the mitochondrial membrane. This
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FIGURE 7 | Mitochondrial electron transport chain in hyperglycemia. Under hyperglycemic conditions, higher levels of glucose-derived pyruvate increase the flux of
NADH and FADH2 into the electron transport chain and consequently increase the proton gradient across the mitochondrial membrane. The transfer of free
electrons to complex III is blocked, leading the electrons to be donated to coenzyme Q10, which then transfers electrons to molecular oxygen, thereby generating
O2−. CoQ10, coenzyme Q10; e−, electrons; O2−, superoxide; GSH, glutathione; GSSG, oxidized glutathione; H2O2, hydrogen peroxide; Pi, inorganic phosphate;
SOD, O2− dismutase.
abnormally high proton gradient blocks complex III, forcing
free electrons to move back to coenzyme Q10, which then
transfers these electrons to molecular oxygen in a process known
as electron leak, thereby generating O2− anions (Rolo and
Palmeira, 2006). As mentioned above, in normal physiological
conditions there is still some mitochondrial ROS being generated
during the electron migration at complex IV; however, it
is within the capacity of the glutathione/peroxidase system
and SOD to scavenge it and prevent buildup of oxidative
stress (Figure 7).
NADPH Oxidase (NOX) Activation and
Endothelial Dysfunction in Diabetes
In addition to the mitochondrial dysfunction being a major
source of hyperglycemia-induced ROS overproduction, studies
have shown there are other principle sources that include:
NOX and uncoupled eNOS (Inoguchi et al., 2000; Volpe et al.,
2018). The NOX family of enzymes were identified first in
phagocytic cells, neutrophils and macrophages. They are the
only family of enzymes with a primary function to generate
ROS (H2O2, O2−) by catalyzing the electron transfer from
cytosolic NADPH to molecular O2 across plasma and lysosomal
membranes (Thannickal and Fanburg, 2000; Salazar, 2018).
There is a total of seven isoforms identified so far which are
abundantly expressed in phagocytic cells. These isoforms include,
NOX1, NOX2, NOX3, NOX4, NOX5, DUOX1 and DUOX2.
Four of these are expressed by endothelial cells, NOX1, NOX2,
NOX4, and NOX5 (Salazar, 2018). In endothelial cells, NOXs are
believed to produce moderate levels of ROS which are needed for
redox signaling during normal cell metabolism process. However,
in certain pathological states, NOX expression and activity in the
vasculature was found to be increased, thus contributing to excess
release of ROS.
NOX isoforms consist of a catalytic subunit “NOX,” which
catalyzes the transfer of free electrons from cytosolic NADPH to
molecular oxygen. Specifically, for NOX-1, 2, and 4, additional
regulatory subunits are also required for a complete activation of
the complex. These subunits include p22phox, p47phox, p67phox,
and p40phox. By contrast to the other isoforms, NOX-5 is a
unique polypeptide subunit which is regulated by Ca2+. One
additional difference between these isoforms is that while NOX-
1, 2, and 5 generate superoxide O2−, NOX-4 generates the
non-charged radical H2O2 (Drummond and Sobey, 2014). The
subunit p47phox is pivotal for NOX activation and is frequently
named the ‘organizer subunit’ since it is crucial for the formation
of an active NOX complex. It resides within the cytosol in
resting state; however, upon its phosphorylation at several serine
residues, it undergoes conformational changes to expose its
intramolecular SH-3 domain which interacts with the cytosolic
activator p67phox subunit, and chaperones it to the membrane-
bound subunits, NOX and p22phox, to finally form the active
NOX complex (Schulz et al., 2011; Drummond and Sobey, 2014).
Hyperglycemia, free fatty acids, and oxidized low-density
lipoprotein (LDL) have been shown to enhance endothelial NOX
activity (Shen, 2010). Vessels isolated from diabetic subjects
exhibit increased O2− production and higher expression levels of
several NOX subunits (p22phox, p47phox, and p67phox), suggesting
that NOX isoforms are more active in diabetes (Pitocco et al.,
2010). The excess of O2− can rapidly react with NO to form
ONOO− which, in turn, oxidizes tetrahydrobiopterin (BH4),
thus making it unavailable for interaction with eNOS. In the
presence of low amounts of BH4, eNOS becomes uncoupled and
donates free electrons to O2 instead of L-arginine, producing
therefore O2− instead of NO. Clinical studies demonstrated
that BH4 supplementation improved endothelium-dependent
vasodilation in diabetic patients, highlighting the important
role of uncoupled eNOS in endothelial cell dysfunction in
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diabetes (Son, 2012). Collectively, hyperglycemia is tightly
associated with NOX activation, mitochondrial dysfunction, and
ER stress response. These cell responses are unequivocally major
mechanisms underpinning ROS overproduction and oxidative
stress-mediated endothelial cell damage in diabetes.
ENDOTHELIAL DYSFUNCTION AND
ALTERED ANGIOGENIC CAPACITY IN
DIABETES: A FOCAL ROLE FOR NO AND
ROS
Blunted eNOS activity and/or protein expression and subsequent
decreased NO bioavailability is a hallmark of endothelial
dysfunction associated with diabetes (Hirata et al., 2010). Protein
expression of eNOS is tightly controlled by several molecular
processes, which include transcriptional and post-transcriptional
regulation of mRNA expression (Searles, 2006), and post-
translational regulation of the protein structure and function
where the role of Akt activity is crucial in enhancing the
phosphorylation of eNOS at Ser1177 causing its activation
(Shen et al., 2006). In early stages of hyperglycemia-induced
cellular stress, high glucose-induced ROS production alters Ca2+
homeostasis leading to Ca2+ leaking from ER stores into the
cytosol (Ding and Triggle, 2010; Triggle and Ding, 2010). As a
result, intra-ER Ca2+ levels fall below a critical level interfering
thus with the activity of many ER chaperones which depend
on Ca2+ availability inside the ER lumen and hence interfere
with proper protein folding leading to activation of UPR and
eventually apoptosis (Morgan et al., 2008). Furthermore, the
resulting increase in cytosolic Ca2+ induces the activation of
eNOS which can produce high amounts of NO that can then
quickly react with O2− to form ONOO−, thereby oxidizing BH4
and eventually leading to eNOS uncoupling and a reduction in
the bioavailability of NO (Ding and Triggle, 2010). In advanced
stages, when ER stress reaches a point where it cannot be resolved,
the cell must activate pro-apoptotic signals. Endothelial cells
incubated in high glucose, activate IRE-1α -mediated cell death
response following a disruption Ca2+ homeostasis due to an
increase in the levels of ROS (Bishara and Ding, 2010).
The activation IRE-1α stimulates JNK and p38
mitogen-activated protein kinases (MAPK) pathways triggering
thus the downstream pro-apoptotic mediators, apoptosis
signal-regulating kinase (ASK)-1 and caspase-12, via CHOP
activation (Xu C. et al., 2005). ASK-1 can cause NO deficiency
by inhibiting eNOS through reduced phosphorylation at
Ser1177 site (Yamashita et al., 2007). A study conducted by
Galan et al. (2014) demonstrated in coronary artery endothelial
cells that were subjected to high glucose or ER stress inducer,
tunicamycin, the role of NOX in the suppression of eNOS
promotor region and decreased phosphorylation. These effects
were restored by a chemical chaperone, 4-PBA, that helped
resolve ER stress. They also reproduced similar results in vivo
by showing a significant reduction in endothelium-dependent
and independent relaxation in control mice compared with
p47phox-deficient mice, indicating the involvement of p47phox
subunit of NOX complex as a molecular link for ER stress-
induced reduction in NO production and the consequent
vascular endothelial dysfunction (Galan et al., 2014). More
recently, it has been reported that high glucose-induced ER
stress caused an increase in the phosphorylation of p47phox at
Ser345 (Maamoun et al., 2017). This critical phosphorylation
was found to precede the activation of NOX (Perisic et al., 2004).
Nevertheless, regardless of the exact mechanisms involved in
the inhibition of eNOS, it is generally accepted that high glucose
induces a reduction in NO production and bioavailability and
hence contributes to endothelial dysfunction.
Micro- and macrovascular beds are altered in diabetes by
various changes in angiogenic mechanisms (Simons, 2005).
However, from a vascular standpoint, diabetes is a paradoxical
disease (Costa and Soares, 2013). Excessive angiogenesis
contributes to the onset of both diabetic retinopathy (Wilkinson-
Berka, 2004) and nephropathy (Osterby and Nyberg, 1987).
Insufficient angiogenesis, however, plays a critical role in several
pathological states including impaired wound healing process,
weak neovascularization of coronary collaterals, embryonic
vasculopathy during gestational diabetes, and acute transplant
rejection in recipients suffering from diabetes (Galiano et al.,
2004). Furthermore, diabetic neuropathy is a complication linked
with reduced nutritive blood flow secondary to diabetes. Altered
arteriogenesis, which is referred to as the process of remodeling
(such as increase in diameter) of arteries, has also been widely
observed in diabetics (Abaci et al., 1999). The weak mobilization
of endothelial progenitor cells (EPC) from bone marrow and their
defective function are also key features of diabetes that can cause
aberrant neovascularization and hence contribute to the increase
of cardiovascular risk (Tepper et al., 2002).
Angiogenesis is a process of formation of new capillary
networks in response to reduced oxygen concentration (hypoxia)
or pro-angiogenic molecular signals. This mechanism implicates
the release of pro-angiogenic factors from both hypoxic
endothelial cells and the their surrounding pericytes, which
stimulate endothelial cell proliferation and sprouting of new
vessels from existing ones (for review see Stapor et al., 2014).
This is different from arteriogenesis, a mechanism involving
the growth and development of existing arterioles following
an acute vascular occlusion (Folkman and Shing, 1992). There
are several equally important hypotheses for the mechanisms
underpinning disturbances in angiogenesis in diabetes, including
a downregulation of VEGF-A signaling response, alterations
in inflammatory signals, activation of ER stress response, and
accumulation of AGEs initiating oxidative stress and over-
production of ROS (Tamarat et al., 2003). Accumulating data
indicate that the impact of ROS on the vasculature depends
essentially on the oxidative level of the environment. However,
the precise amount of ROS needed to cause vascular dysfunction
is difficult to predict. Under basal conditions, low ROS levels,
especially hydrogen peroxide, can work as intracellular secondary
messengers to modulate the action of pro-angiogenic factors such
as VEGF-A; however, higher levels of ROS can conversely disturb
neovascularization process (Griendling and FitzGerald, 2003a,b).
Several ROS species, including O2−, H2O2, OH− radicals,
lipid peroxides, and ONOO−, have been recognized to play
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major roles in vascular biology controlling the angiogenic
process (Tojo et al., 2005). Ebrahimian et al. (2006) reported
that diabetes-mediated oxidative stress impaired post-ischemic
neovascularization. Authors found that the reduction of ROS
production restored key pro-angiogenic signaling pathways (e.g.,
VEGF-A). Nishikawa et al. (2000) proposed that high glucose-
mediated mitochondrial production of ROS can stimulate several
molecular mechanisms involved in aberrant angiogenesis. Other
studies indicated that O2− release by NOX complex plays a key
role in VEGF expression and angiogenesis in a mouse model
for diabetic ischemic vascular disease. In addition, increased
expression of NADPH subunit NOX2 (gp91phox) has been found
to correlate with increases in ROS and decreased VEGF-A
in ischemic diabetic retinopathy (Al-Shabrawey et al., 2008).
Furthermore, high levels of O2− production by NOX are likely
to scavenge NO or cause eNOS uncoupling and hence reduce
NO bioavailability (Guzik et al., 2002). These changes in NO
signaling pathway may also contribute to the regulation of post-
ischemic angiogenic process because of the well-documented role
of NO as a key modulator of bone marrow mononuclear cell
(MNC) mobilization, differentiation and homing (Aicher et al.,
2003). Tepper et al. (2002) reported that the phosphorylation and
activation of p38 MAPK by diabetes-induced ROS production
leads to impaired differentiation of bone marrow MNC into
EPC in vitro and impaired their pro-angiogenic capacity in vivo.
Diabetes has also been shown to activate p38 MAPK in vascular
wall via signaling pathways that may involve PKC (Igarashi
et al., 1999). The activation of p38 MAPK is known to
downregulate EPC proliferation and differentiation which may
further contribute to impaired angiogenesis in diabetes. Not only
has development of oxidative stress with increased production
of ROS been reported in in vitro and in vivo diabetic models
of impaired angiogenesis, but also the anti-oxidant defense
capacity is reduced which can also contribute to diabetes-induced
oxidative stress (Wohaieb and Godin, 1987). Previous reports
showed that chronic exposure of HUVECs to high glucose
caused suppression of kelch-like ECH-associated protein (Keap)-
1/erythroid 2–related factor (NrF)-2 pathway which is the major
modulator of cytoprotective responses to stresses mediated by
ROS including the HO system. The suppression of Keap1/NrF-
2 correlated with impaired migration and tube-like formation
capacity of HUVECs (Chen et al., 2015) (Figure 8).
HO-1 AND ITS PROTECTIVE EFFECTS
AGAINST DIABETES-MEDIATED
ENDOTHELIAL DISTURBANCES
Heme oxygenases are a group of anti-oxidant enzymes that
play a pivotal role controlling intracellular levels of heme by
mediating the biodegradation of heme to release the following
byproducts, Fe2+, CO, and biliverdin in mammalian cells
(Kikuchi et al., 2005; Ryter et al., 2006; Abraham and Kappas,
2008; Rochette et al., 2018). Biliverdin, a water-soluble molecule,
is then metabolized by biliverdin reductase into bilirubin. In
diabetes and other cardiovascular disorders such as hypertension,
the excess of free heme leads to the formation ROS species,
which in turn contribute to the onset of endothelial dysfunction.
The HO system, by metabolizing the excess heme, can generate
various byproducts, which may initiate different cytoprotective
cardiovascular effects: (I) Pro-survival effect on endothelial cells;
(II) Reduced inflammation and oxidative stress in vasculature;
(III) Improved vascular homeostasis and control of the vascular
tone regulation; and (IV) Enhanced neovascularization. Bilirubin
and biliverdin are the two main active byproducts of HO
action and are considered as the strongest scavengers of ROS
in the body; however, CO can have anti-apoptotic and anti-
inflammatory roles via the activation of guanylyl cyclase (Stocker
et al., 1987; Nitti et al., 2017). CO is capable of suppressing
the release of key inflammatory molecules such as of TNF-α
and IL-1β and stimulating the synthesis of the human cytokine-
synthesis inhibitory factor (CSIF or IL-10) (Otterbein et al.,
2000). The last byproduct of heme degradation is free iron,
which despite participating in Fenton reaction, which generates
the very reactive OH− radical, also activates Fe/ATPase pump,
which pumps free iron outside of the cell and enhances protein
expression of ferritin which can then scavenge free iron and exert
therefore beneficial effects (Crichton et al., 2002).
Three HO isoforms have been reported in humans: HO-
1 (32 KDa), which is the inducible form, and two other
isoforms with constitutive expression [HO-2 (36 KDa) and a
putative HO-3 (33 KDa)] (Nitti et al., 2017). The inducible
HO-1, is expressed at very small amounts in normal tissues,
except the liver and spleen, where it plays a key role in
the elimination process of damaged and aged red blood cells
(Gottlieb et al., 2012). Protein expression of HO-1 can be
enhanced by many stimuli, which can induce ROS production.
Among the pharmacological and chemical stimuli known to
induce HO-1, there is heme itself [a byproduct of HO-1 action),
heavy metals (e.g., cobalt], inflammatory cytokines, ultraviolet
radiation, bacterial membrane component lipopolysaccharide
(LPS), hyperglycemia, H2O2, cell growth factors, NO, and CO
(Ryter et al., 2006). On the other hand, the expression of HO-2
is not induced by the factors inducing HO-1. However, HO-2 is
constitutively expressed in high levels in certain tissues such as
the brain, testis, smooth muscle cells and endothelial cells (Chen
et al., 2003). In addition to maintaining heme homeostasis, basal
amounts of HO-2 also play a key role in anti-oxidant cellular
responses by regulating the activation of extracellular SOD,
Akt, and ASK-1, through the modulation of heme degradation
rate into its biological byproducts. Furthermore, HO-2 plays
a pivotal role in sensing levels of oxygen and in cellular
response to hypoxia (Munoz-Sanchez and Chanez-Cardenas,
2014). The protective role of HO-2 in hypoxia was demonstrated
in endothelial cells. HUVECs and aortic endothelial cells exposed
to hypoxia were found to exhibit a stable HO-2 protein
expression despite a significant decline in its mRNA expression
and a decrease in general protein translation. An increased
interaction of HO-2 transcript with polysomes was observed
during hypoxic events, leading to a selective activation of HO-2
protein translation, which maintained protein expression levels
of HO-2. The maintenance of steady levels of HO-2 protected
endothelial cells from apoptosis during hypoxic episodes (He
et al., 2010). Finally, HO-3 is encoded by a pseudogene derived
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FIGURE 8 | Mechanisms of aberrant angiogenesis induced in hyperglycemia. Increased ROS production in hyperglycemic environment both in vitro and in vivo is
believed to cause insult on the angiogenic process. Theories proposed include suppression of VEGF-A signaling, suppression of EPC mobilization, proliferation and
differentiation, reduction in NO bioavailability and suppression of Keap1/NrF-2 pathway with resultant suppression in HO-1 expression. EPC, Endothelial progenitor
cell; Keap1, Kelch-like ECH-associated protein 1; NrF-2, nuclear factor erythroid 2–related factor 2; VEGF-A, Vascular endothelial growth factor A. The symbol
means inhibition.
from the transcript of HO-2, but so far has only been identified in
rats (McCoubrey et al., 1997).
The modulation of HO-1 expression involves a complex
molecular interplay between different regulatory mechanisms.
MAPK, phosphatidyl inositol 3-kinase (PI-3K)/Akt, protein
kinases (PKA, PKC, and PKG) (Stocker and Perrella, 2006),
NrF-2, activator protein (AP)-1, NF-κB, cyclic adenosine
monophosphate-response element-binding (CREB) protein, and
activation transcription factor (ATF)-2 are signaling pathways
that have been found to play a role in gene regulation of
HO-1 expression (Kim H.P. et al., 2011; Kim Y.M. et al.,
2011). Of particular interest, in response to oxidative damage,
NrF-2 controls the transcriptional induction of HO-1. NrF-2
is maintained in inactive form in the cytosol by interacting
with protein Keap1, which prevents the nuclear translocation
of NrF-2 and enhances proteasome-mediated degradation of
NrF-2. Following induction of an oxidative stress state, NrF-
2 is activated after its dissociation from Keap1; active NrF-2
translocates then to the nucleus and triggers the transcription of
HO-1 gene. In support of the role of NrF-2 in controlling HO-
1 expression, previous reports have found that fibroblasts from
mice deficient in NrF-2 express low levels of HO-1 (Leung et al.,
2003; Liu et al., 2007).
Several heavy metal protoporphyrins induce the expression
of HO-1; however, Cobalt protoporphyrin (CoPP) is regarded
as probably the most potent. CoPP indirectly modulates the
production of two factors involved in regulating the expression
of HO-1, NrF-2 and transcription regulator protein Bach1.
Bach1 is a basic leucine zipper transcription factor that forms
heterodimers with proteins from the Maf family and repress the
transcription of the HO-1 gene. CoPP enhances the degradation
of Bach1 protein. NrF-2 is also a member of the family of
basic leucine zipper transcription factors, which is involved
in protection against oxidative stress through its antioxidant
response element (ARE)-directed induction of HO-1. CoPP
also induces the overexpression of NrF-2 by decreasing its
degradation, and being a basic leucine zipper transcription factor,
the NrF-2 dimerizes with the Maf family transcription factors
and together these heterodimers bind to ARE of the HO-1
promotor region resulting in enhancement in expression (Shan
et al., 2006). Liu et al. (2013) also reported that CoPP increases the
expression of the transcription factor forkhead box protein O1
(FOXO1), which results in transcriptional upregulation of HO-1
gene (Liu et al., 2013).
Besides this mRNA transcriptional activation of HO-1, it
was found that HO-1 is also subjected to a post-transcriptional
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regulatory process which aims at reducing the expression of HO-
1 to prevent that its overexpression becomes constitutive. This
negative regulation of HO-1 expression is under the control
of two microRNA (miR) molecules, miR-217 and miR-377,
which work together to reduce the mRNA levels of HO-1
and hence reduce its protein expression. Knocking down these
two microRNA molecules abrogated the attenuation of HO-1
expression (Beckman et al., 2011). Lin P.H. et al. (2008) showed
that HO-1 expression is also regulated by a post-translational
mechanism under the action of the ubiquitin/proteasome
system. These findings were further supported by the increased
HO-1 expression in the presence of proteasome inhibitor,
MG-132, in a model of heme-induced oxidative damage
(Chen and Regan, 2005).
Role of HO-1 in Vascular Inflammation
It has been established that HO-1 is able to suppress
inflammatory responses by the concomitant generation of CO
and bilirubin, two anti-inflammatory molecules, and the removal
of pro-inflammatory agent, heme. CO and bilirubin are reported
to blunt both innate and adaptive immune responses by
modulating the activation and functions of multiple cell types
involved in inflammation such as immune cells, endothelial cells
and platelets, which ultimately results in reduced recruitment
and tissue infiltration of immune cells (Durante, 2011). The anti-
inflammatory role of HO-1 was determined in HO-1 knockout
mice. In these mice, HO-1 deficiency led to higher release of
pro-inflammatory molecules (Kapturczak et al., 2004). In patients
undergoing a surgery, higher levels of HO-1 were associated
with lower levels of pro-inflammatory cytokine IL-6 (Taha et al.,
2010). HO-1 was found to lower leukocyte rolling, adhesion,
and transmigration to the sub-intimal space, by blunting the
expression and function of surface adhesion molecules. In
contrast, the inhibition of HO-1 caused the overexpression and
over activation of adhesion molecules, activating thus leukocyte
recruitment (Belcher et al., 2006). Multiple preclinical and clinical
studies have been performed in many inflammatory vascular
diseases to understand the impact of HO-1 overexpression on
the pathogenesis and progression of the inflammatory process.
Much evidence shows that the induction of HO-1 in the vessel
wall inhibited the transmigration of monocytes to the sub-intimal
space facilitated by oxidized low-density lipoproteins (LDL),
leading to reduced atherosclerotic lesion buildup in mice lacking
LDL receptor, a widely used model for atherosclerosis (Ishikawa
et al., 2001). Circulating amounts of bilirubin in the general
public were found to negatively correlate with the incidence of
ischemic accidents (Mayer, 2000). This is not surprising knowing
that bilirubin was found to decrease endothelial activation and
dysfunction (Kawamura et al., 2005).
Role of HO-1 in Angiogenesis
HO-1 and its gas byproduct CO have been recognized for their
strong pro-angiogenic roles. Several pro-angiogenic molecules,
including VEGF, were found to mediate their effects via the
induction of HO-1. However, depending on the situation, the
pro-angiogenic properties of HO-1 could be considered as
beneficial or deleterious. For instance, favoring angiogenesis is
critical for many physiological responses such as wound healing
and neovascularization following an ischemic episode. However,
activation of angiogenesis driven by HO-1 may be deleterious in
other conditions such neoplastic states (Dulak et al., 2008).
In investigating the role of HO-1 in promoting angiogenesis,
Zhao et al. (2011) found that partial deficiency of maternal HO-1
caused defects in the feto-maternal interface, structural defects in
placental vasculature and deficiency in spiral artery remodeling.
These alterations were not related to the fetal genetic background
and were only dependent on the maternal genetic status of HO-
1. Moreover, restoring blood flow and the reestablishment of
optimal oxygen concentrations to an injury site are also achieved
by a proper angiogenic process. The wound-healing sequence
of events consists of multiple steps that all require an intact
angiogenesis process (Bauer et al., 2005). Growth factors (e.g.,
VEGF), chemokines, and hypoxia-inducible factors (HIF) all
contribute to the orchestration of the multi-step wound healing
procedure (Tepper et al., 2005). The deletion of HO-1 in mice
led to an impaired wound healing process compared to wild-
type littermates. This was partly because of an impaired EPC
mobilization capacity linked to capillary formation at the site
of injury (Deshane et al., 2007). Furthermore, it has been noted
that the natural activation of HO-1 expression in wounded
skin areas was weaker and slower in diabetic mice compared
to controls. In these animal models of diabetes, the local
adenoviral-mediated delivery of HO-1, improved the wound
healing process (Grochot-Przeczek et al., 2009). Furthermore,
HO-1 was found to confer a cytoprotective role in ischemic
cardiac tissue through the activation of protein expression of
pro-angiogenic factors in infarcted areas of cardiac tissue (Zeng
et al., 2010). Lin H.H. et al. (2008) observed that the transfer
of the HO-1 gene to infarcted heart tissue confers protection,
at least partly, through the activation of VEGF-A expression
and the subsequent activation of angiogenesis. In addition, the
overexpression of HO-1 in mesenchymal stem cells implanted
in infarcted hearts, markedly reduced apoptosis and fibrosis in
cardiac tissue and improved cardiac function and remodeling
(Jeon et al., 2007). Recently, Maamoun et al. (2017) have reported
that the incubation of HUVECs in intermittent high glucose
conditions for 5 consecutive days caused the activation of ER
stress response and an impaired capacity of cells to form tube-
like structures on a 3-dimensional matrigel matrix. This effect was
associated with a decrease in the mRNA and protein expression
of VEGF-A, indicating reduced angiogenesis capacity in these
cells. Authors found that the pharmacological induction of HO-1
with CoPP reduced ER stress response and prevented the effects
of high glucose-mediated ER stress on angiogenic capacity of
cells, further stressing the pro-angiogenic effects of HO-1 in
endothelial cells (Maamoun et al., 2017).
It is crucial to also highlight that despite the evidence in
literature in support of the beneficial role of HO-1 in angiogenesis
control, some reports identified a negative impact of HO-1 in
tumoral neovascularization. Some human tumors, such as renal
cell carcinoma and prostate cancer, exhibit elevated expression
levels of HO-1 (Goodman et al., 1997). HO-1 could therefore
contribute to tumor cell growth, survival and progression
and ultimately participate in the resistance to drug therapy
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(Nowis et al., 2006). In these conditions, the inhibition of
HO-1 reduced tumor development in murine cancer models
indicating a potential therapeutic role for HO-1 inhibition in
certain cancer types (Dulak et al., 2008). However, there are
also some reports that show HO-1 may play an anti-angiogenic
role in certain cancer situations. In prostatic cancer cells (PC3),
Ferrando et al. (2011) found that the overexpression of HO-
1 caused the downregulation of several pro-inflammatory and
angiogenic factors (NF-κB, VEGF-A, VEGF-C). To model the
in vivo angiogenic process, the authors intradermally inoculated
PC3 cells, that had been transfected with a stable HO-1 DNA
construct, into immunodeficient mice and found that these cells
produced tumors that were less richly vascularized than controls
(Ferrando et al., 2011). However, in other conditions driven by
excessive angiogenesis such as diabetic retinopathy (Wilkinson-
Berka, 2004) and nephropathy (Osterby and Nyberg, 1987), HO-
1 induction was still reported to be protective, indicating the
complexity of the physiological actions of HO-1. For instance,
Fan et al. (2012) observed in streptozotocin-injected diabetic rats
pre-injected with hemin, a HO-1 inducer, that retinal ganglion
cells were less prone to apoptosis compared to controls (not
pre-treated with hemin), suggesting that HO-1 induction in rat
retinas protected against diabetes-mediated neurodegeneration.
Furthermore, the expression levels of VEGF, a strong pro-
angiogenic factor which contributes to exaggerated angiogenesis,
was also attenuated in retinas from streptozotocin-injected rats
treated with hemin (Fan et al., 2012).
Taken together, data outlined here identify HO-1 as
a key modulator of the angiogenic process in different
pathophysiological conditions. Therefore, HO-1 induction
could be a potential therapeutic target for the inhibition of
angiogenesis in carcinogenic conditions, as opposed to being a
therapeutic target for the induction of angiogenesis in diabetic
cardiovascular complications. These studies also highlight the
complexity of signaling pathways underpinning the action of
HO-1 in angiogenesis.
Role of HO-1 in Oxidative Stress
The most well-known properties of HO-1 are its anti-oxidant
functions (Hayashi et al., 1999). Of particular note, the work
conducted by Ishikawa et al. (2012) demonstrated that mice
lacking the gene of HO exhibited a weaker anti-oxidant capacity
and an extensive lipid peroxidation. The anti-oxidant capacity
of HO-1 is due to its byproducts biliverdin and CO. Bilirubin
strongly scavenges several oxygen free radicals including singlet
oxygen, O2−, ONOO− and RO2 radicals. Moreover, unlike GSH,
bilirubin, because of its lipophilic nature, is closely associated
with cell membranes, and hence protects them against lipid
damage by peroxidation. Bilirubin was found to work better as
an O2− scavenger and inhibitor of ONOO−-mediated protein
nitration than biliverdin (Jansen et al., 2010). In addition to
its ROS scavenging properties, some studies proposed that the
protective actions of bilirubin are also partly related to its
capacity to inhibit inducible NOS (iNOS), which eventually leads
to less production of the highly reactive and potent ONOO−
free radical (Wang et al., 2004). CO also mediates part of the
global anti-oxidant actions of HO-1 (Srisook et al., 2006). CO
was reported to block ONOO−-mediated protein nitration in
endothelial cells through heightened intracellular GSH levels
(Li et al., 2007). The anti-oxidant role of HO-1 was further
demonstrated recently in HUVECs treated with intermittent
high glucose. Authors reported that the induction of HO-
1 using CoPP prevented high glucose-mediated concomitant
increase in superoxide production and reduction in NO release,
indicating an improved NO bioavailability. These focal effects
were associated with a decrease in ER stress response activation,
reduced phosphorylation of NOX regulatory subunit p47phox
at Ser345, and an enhanced phosphorylation of eNOS at its
activatory site (Ser1177) (Maamoun et al., 2017).
There is accumulating evidence that oxidative stress
contributes to the early stages as well as the maintenance
and progression of diabetic cardiovascular complications.
Therefore, HO-1, owing to its strong anti-oxidant properties,
may be utilized as a viable and promising therapeutic target in
these conditions. The protective actions of HO-1 induction have
been demonstrated in animal models of diabetic cardiomyopathy
and vasculopathy (Li et al., 2012). Moreover, in vitro studies
have demonstrated the highly potent anti-oxidant effect of
bilirubin with increased protection of vascular endothelial cells,
where even concentrations of bilirubin in the nanomolar range
protected cells against oxidative stress damage both through
direct scavenging of ROS radicals and indirectly by blocking the
activity of NOX complex (Abraham and Kappas, 2008).
Role of HO-1 in Apoptosis
A high percentage of apoptotic endothelial cells was observed
in animal models of diabetes-mediated vascular injury (Negi
et al., 2011). Clinical data also suggest the involvement of
apoptosis in diabetic vascular diseases where the expression
of pro-apoptotic molecules was high while in contrast the
expression of anti-apoptotic ones was low (Arya et al., 2011).
HO-1 mediates its anti-apoptotic action through multiple
molecular mechanisms including the inhibition of oxidative
stress, ER stress and inflammation. NF-κB was shown to
control cellular apoptosis in addition to its well-known role
in inflammation. HO-1 induction by CoPP was found to
reduce the expression of IL-6, a gene regulated by NF-
κB, and CHOP in response to stressful stimuli such as
ischemia-reperfusion injury, with the consequent inhibition of
apoptosis (Ben-Ari et al., 2013). Other mechanisms suggested
for the anti-apoptotic effects of HO-1 include blunting the
apoptotic signaling pathway mediated by the interaction of
TNF-α with its receptor (Jaeschke and Woolbright, 2013).
These anti-apoptotic actions of HO-1 may be driven by
the release of CO, which was shown to protect against
apoptosis in many cell types, including endothelial cells,
fibroblasts, hepatocytes and pancreatic β-cells. Brouard et al.
(2000) were able to show that HO-1 inhibits apoptosis,
namely by generating CO. The inhibition of HO-1 activity
by tin protoporphyrin (SnPPIX) failed to prevent endothelial
cell apoptosis. The direct effect of CO on apoptosis was
confirmed by showing that exposing endothelial cells to
exogenous CO, while inhibiting HO-1 activity by SnPPIX,
prevented apoptosis. Moreover, investigators have also explored
Frontiers in Physiology | www.frontiersin.org 15 February 2019 | Volume 10 | Article 70
fphys-10-00070 February 7, 2019 Time: 18:22 # 16
Maamoun et al. HO-1 and Diabetic Endothelial Dysfunction
some of the signaling pathways behind the action of HO-1/CO,
and showed that it is partially mediated by the activation of
p38 MAPK signaling transduction pathway. This was further
supported by the observation that the selective blockade of p38
MAPK by the over-expression of a dominant negative mutant
resulted in the abolishment of the anti-apoptotic effect of HO-
1 (Brouard et al., 2000). In addition, as previously discussed, in
diabetic vascular disease, oxidative stress occurs in endothelial
cells which subsequently leads to apoptosis. Hence, HO-1 by
merely exerting its anti-oxidant effects is reported to protect
these cells from apoptosis (Schmeichel et al., 2003). Other
studies focused on the role of bilirubin in this pro-survival
behavior of HO-1. It has been shown that bilirubin was found
to mediate its anti-apoptotic role by upregulating extracellular-
signal-regulated kinase (ERK) MAPK and PI-3K/Akt/eNOS
pathways (Hung et al., 2010).
More recently, pharmacological induction of HO-1 using
CoPP was reported to protect endothelial cells from high glucose-
mediated apoptosis through the alleviation of ER stress response.
Maamoun et al. (2017) observed that the exposure of HUVECs
to intermittent high glucose for a duration of 5 days led to
cell death, while induction of HO-1 prevented this deleterious
manifestation. The cytoprotective effects of HO-1 were associated
with a reduction in the activation of PARP-1 and caspases 3
and 7. Furthermore, HO-1 induction in HUVECs prevented
the activation of NF-κB and JNK pathways caused by high
glucose treatment, indicating reduced cellular inflammation in
the presence of HO-1 (Maamoun et al., 2017). While the amount
of scientific evidence is still relatively small, some studies suggest
HO-1 activation as a novel and promising strategy to improve
survival of endothelial cells through HO-1 byproducts, bilirubin
and CO, which may delay the development of various diabetic
cardiovascular complications.
CONCLUSION
Crosstalk between oxidative stress and ER stress significantly
contributes to the onset and development of endothelial
dysfunction and altered angiogenesis and therefore represent
major therapeutic targets for alleviating micro- and
macrovascular complications associated with this metabolic
disturbance. HO-1 carries out, anti-oxidant, anti-inflammatory,
anti-apoptotic and angiogenic actions, through its by-
products CO and bilirubin, and can thus affect therefore
multiple cellular pathways involved in endothelial dysfunction,
including oxidative stress and ER stress response. As a multi-
target molecule affecting major aspects of cardiovascular
dysfunction, HO-1 induction represents a potential therapeutic
approach for cardiovascular complications associated
with diabetes.
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